BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Driving Innovation and Collaboration: TransCelerate BioPharma Champions the Future of R&D

  January 31, 2025

   · 

  4 min read
• Press Releases

  Virpax’s Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

  January 31, 2025

   · 

  3 min read
• Press Releases

  Delta4 Secures European Patents for Two Compounds as Candidate Treatments for Focal Segmental Glomerulosclerosis (FSGS)

  January 31, 2025

   · 

  1 min read
• Press Releases

  Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade

  January 31, 2025

   · 

  4 min read
• Press Releases

  Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

  January 31, 2025

   · 

  3 min read
• Press Releases

  Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

  January 31, 2025

   · 

  7 min read
• 

  Layoffs

  Fractyl Goes All In on GLP-1 Off-Ramp Drug, Lays of 17% of Workforce

  Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and parting with around 22 employees in an attempt to extend its runway into 2026.

  January 31, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  IRA

  Drug Pricing and the Uncertain Future of the IRA Under Trump

  While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug prices in the U.S., Trump has so far been mum on how the controversial law could evolve in the coming years.

  January 31, 2025

   · 

  4 min read

   · 

  Jef Akst
• 

  Earnings

  AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure

  After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.

  January 31, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Layoffs

  ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva

  ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

  January 31, 2025

   · 

  1 min read

   · 

  Angela Gabriel